Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Curevac N.V.
(NQ:
CVAC
)
2.760
+0.020 (+0.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Curevac N.V.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial
March 30, 2022
Via
Benzinga
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
March 30, 2022
- Phase 1 dose-escalation study started at clinical sites in the U.S. - Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine...
From
CureVac
Via
AccessWire
Exposures
COVID-19
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
March 01, 2022
- The RNA Printer(R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics - CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate...
From
CureVac
Via
AccessWire
Exposures
COVID-19
Why CureVac Shares Are Falling
October 15, 2021
CureVac BV (NASDAQ: CVAC) shares are trading lower after the company and Bayer reportedly terminated their vaccine manufacturing partnership. More news came around 1:20 pm...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
February 16, 2022
We've got another busy day of trading ahead of us so let's get right to it with the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
February 15, 2022
We've got another busy day of trading ahead of us and we're starting with the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK
February 10, 2022
- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains - Influenza candidate developed in collaboration with GSK within broad...
From
CureVac
Via
AccessWire
53 Biggest Movers From Friday
January 24, 2022
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares climbed 100% to close at $3.80 on Friday after gaining around 9% on Thursday. Dave Inc. (NASDAQ: DAVE) jumped 30.3% to settle...
Via
Benzinga
CVAC Stock Alert: Why Is Vaccine Maker CureVac Plunging Today?
January 21, 2022
Amid broadly bearish market sentiment, investors in CureVac and CVAC stock are in selling mode, as this stock receives a downgrade.
Via
InvestorPlace
34 Stocks Moving In Friday's Mid-Day Session
January 21, 2022
Gainers Blue Star Foods Corp. (NASDAQ: BSFC) shares jumped 180% to $5.32 after gaining around 9% on Thursday. Bon Natural Life Limited (NASDAQ: BON) shares gained 22% to $3.91....
Via
Benzinga
BofA Downgrades CureVac On Limited 2022 Prospects
January 21, 2022
There is limited upside from CureVac BV’s (NASDAQ:CVAC
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022
January 21, 2022
Upgrades According to Seaport Global, the prior rating for KB Home (NYSE:
Via
Benzinga
Chopped Stocks
January 18, 2022
The day's theme is sell tech and buy banks.
Via
Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
January 18, 2022
Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE:
Via
Benzinga
52 Biggest Movers From Friday
January 18, 2022
Gainers Splash Beverage Group, Inc. (NASDAQ: SBEV) shares gained 118.9% to settle at $4.18 on Friday. Splash Beverage recently announced it has received authorization to sell its...
Via
Benzinga
CureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
January 17, 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / January 17, 2022 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
30 Stocks Moving In Friday's Mid-Day Session
January 14, 2022
Gainers ATI Physical Therapy, Inc. (NYSE: ATIP) shares gained 25.2% to $3.8050 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $3.50 to $5....
Via
Benzinga
dievini and the Federal Republic of Germany Amend Shareholders’ Agreement Regarding Investments in CureVac N.V.
January 13, 2022
BERLIN, GERMANY / ACCESSWIRE / January 13, 2022 / Today dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für...
From
dievini Hopp BioTech holding GmbH & Co. KG
Via
AccessWire
CureVac Outlines Upcoming Catalysts For Vaccine Programs
January 10, 2022
Ahead of J.P. Morgan Healthcare Conference, CureVac BV (NASDAQ: CVAC) outlined the timeline for its vaccine programs. CureVac's preclinical second-...
Via
Benzinga
The 'Highly Mutated Virus' Signals A Need For Annual Shots: BioNTech CEO
December 03, 2021
The omicron variant signals a need for annual Covid shots, BioNTech's CEO said.
Via
Investor's Business Daily
56 Biggest Movers From Friday
November 29, 2021
Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been contracted to support new advanced research on...
Via
Benzinga
48 Stocks Moving In Friday's Mid-Day Session
November 26, 2021
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel companies, including Allied Healthcare Products, traded...
Via
Benzinga
CureVac (CVAC) Q3 2021 Earnings Call Transcript
November 19, 2021
CVAC earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
November 19, 2021
- Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review - Nature publication of...
From
CureVac
Via
AccessWire
Topics
Death
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Death
Intellectual Property
CureVac's COVID-19 Vax Shows Comparable Antibody Levels To Pfizer/BioNTech's Shot In Animal Study
November 18, 2021
CureVac BV (NASDAQ: CVAC) has announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Pfizer Strikes $5.29B COVID Pill Supply Deal With US, Roche's Spark Therapeutics Reports Positive Gene Therapy Readout, EDAP Earnings
November 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia...
Via
Benzinga
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
November 18, 2021
TÜBINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / November 18, 2021 / CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
CureVac Presents Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response
November 10, 2021
- Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected lesions - Expansion part of Phase 1 study fully recruited;...
From
CureVac
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Vaccine Makers Slump As Oral Antivirals Begin To Take Center Stage
October 18, 2021
Vaccine makers have been under tremendous selling pressure over the past 2 months driven by policy, the rising delta wave, and breakthrough infections. This slump has been a boost for the oral...
Via
Talk Markets
51 Biggest Movers From Friday
October 18, 2021
Gainers LM Funding America, Inc. (NASDAQ: LMFA) shares jumped 38.1% to close at $4.75 on Friday after declining around 15% on Thursday. The company recently announced it...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.